Gene Variation May Double Odds of Follicular Lymphoma

The Arizona Republic, among other outlets, is reporting on genetic research coming out of U.C. Berkeley and Phoenix-based Translational Genomics Research Institute.

The scientists claim they've found a gene variant that comes close to doubling the risk for developing follicular lymphoma (FL).

Published online in the science journal Nature Genetics, the conclusion was reached after examination of over 3,000 HIV-free DNA samples (since FL occurs in about one in ten HIV patients, future studies may involve HIV-positive patients) and looking for the single-letter difference among 3-billion based pairs of the human genome.

They found the mutation in the STG gene, also known as C6orf15.

What does this mean for people with FL right now? Not much. What does it mean for future generations? That their FL could be diagnosed earlier than it is now, and that certain drugs could be developed that could tackle the disease before it gets a chance to develop.

Either way, it's all a long ways off.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap